GATC Leadership Takes the Stage at Precision in Clinical Trials and Precision Drug Discovery & Preclinical Summits

IRVINE, Calif., October 26, 2026 –  Members of the GATC Health leadership team recently spoke at two premier industry events in San Diego: the Precision in Clinical Trials Summit and the Precision Drug Discovery & Preclinical Summit. Across the two events, the team showcased how GATC’s proprietary AI platform, Operon®, and its Derisq® report, predict clinical risk and delivers targeted solutions across therapeutic areas.

Ian Jenkins, Chief Science Officer, and Vaishnavi Narayan, Head of AI Engineering, participated in panel discussions on AI in drug discovery and clinical trial design. In separate sessions, Chief Business Officer Tyrone Lam co-presented alongside Jenkins for the clinical trials track and Narayan for the drug discovery track, showcasing Operon and the Derisq report while answering audience questions.

Jenkins and Narayan contributed to prominent panel discussions, with Jenkins exploring the delegation of operational tasks to Agentic AI in clinical operations by 2027 and Narayan addressing Agentic AI’s real-world applications in drug discovery. In addition, Lam co-presented in two separate track sessions—partnering with Jenkins for the clinical trials track and Narayan for the drug discovery track—to showcase Operon and the Derisq report while taking questions from audience members.

The enthusiastic reception and deep engagement GATC Health received across both summits underscore the growing market awareness and demand for the company’s innovative, AI-driven solutions.